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Employment of nanovehicular system for delivering apoptogenic agent to cancer cells for inducing apoptosis has
widely been investigated. Loading efficacy and controlled release of the agents are of the inseparable obstacles
that hamper the efforts in reaching an efficacious targeted cancer therapy method. When the carrier itself is
apoptogenic, then there is no need to load the carrier with apoptogenic agent and just delivering of the particle to
the specific location matters. Hence, we hypothesize that amorphous calcium phosphate nanoparticle (ACPN) is a
potent candidate for apoptosis induction, although encapsulation in liposome shell, and surface decoration with
targeting ligand (TL), and cell-penetrating peptide (CPP) plays a pivotal role in the employment of this agent. It is
well understood that elevation in cytosolic Ca2+ ([Ca2+]c) would result in the induction of apoptosis. ACPN has the
potential to cause imbalance in this medium by elevating [Ca2+]c. Owning to the fact that the nanoparticles should
be delivered into cytosol, it is necessary to trap them in a liposomal shell for evading endocytosis. It was demon-
strated that employment of the trans-activator of transcription (TAT) as CPP eminently enhances the efficacy of
endosomal escape; therefore, the platform is designed in a way that TAT is positioned on the surface of the lipo-
some. Due to the fact that the apoptosis should be induced in sole cancer cells, Folate as TL is also attached on the
surface of the liposome. This hypothesis heralds the new generation of chemotherapeutic agents and platforms
which could have less side effect than the most common ones, in addition to other advantages they have.
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Targeting ligandBackground
Many chemotherapeutic agents with different mecha-
nisms of action have been developed up to now. Apop-
tosis induction is one of the mechanisms which has
attracted researchers' attention for fighting against can-
cer [1]. Doxorubicin [2], daunorubicin [3], idarubicin [4],
bleomycin [5], mitomycin C [6], cisplatin [7], plicamycin
[8], and carmustine [9] are of the well-known apopto-
genic agents; although in order to serve them in targeted
drug delivery system, appropriate drug carriers should
be employed. Such carriers are aimed to facilitate drug* Correspondence: vahid.hosseini@hest.ethz.ch
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distribution, and reproduction in any medium,delivery procedure and avoid problems like bioavailabil-
ity and normal tissue toxicity. In this regard, the issues
such as loading efficacy and controlled release of the
agents are of the inseparable obstacles that researchers
are confronted with up to now. The development of an
agent that possesses the favorable drug carrier character-
istics and acts as an apoptogenic agent by itself could be
a promising method for coping with the mentioned
obstacles.
Calcium phosphate minerals are mostly known as
bone substitutive materials due to their outstanding
biocompatibility [10]. Employing nanotechnology has led
to develop these biomaterials in nanoscale range, al-
though some of the studies reported the cytotoxic effect
of hydroxyapatite (one of calcium phosphate crystallinensee Springer. This is an open access article distributed under the terms of the
reativecommons.org/licenses/by/2.0), which permits unrestricted use,
provided the original work is properly cited.
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cells through apoptosis induction [11-16]. This adverse
effect was also observed in other cell lines such as
macrophage, granulose, epithelial, and muscle [17-20].
Interestingly, it was demonstrated that HANs also could
have toxic effect on cancer cells through triggering the
apoptosis, which leads to cell death and inhibits prolifer-
ation [12,21-28]. Based on the abovementioned facts, it
could be suggested that HAN has the potential to serve
as an apoptogenic agent.
Always, there are associate risks and adverse effects
of administrated chemicals, drugs, and medicine via
nanocarriers such as calcium phosphate nanoparticles
(CPNs). In this study, it is aimed to reduce such risks by
employing CPN as an anticancer agent, not as a drug
carrier. This hypothesis is not in contrast with using
CPNs as drug delivery vehicles and it can be used for
such purposes such as gene delivery, but here, the po-
tency of amorphous calcium phosphate nanoparticles
(ACPNs) for cancer therapy is highlighted. As long as
this hypothesis matters, two issues are brought up: (i)
whether only HAN induces this effect in cells or other
CPNs possess this potential and (ii) the steps toward de-
velopment of a favorable platform in order to be utilized
in cancer therapy. Therefore, through the presented
hypothesis, we suggest that ACPN could serve as an
apoptogenic agent in cancer treatment by employing a
suitable targeted drug delivery platform.Figure 1 Schematic diagram of the designed platform and its mechan
cancer cell, (c) penetration of CPP in liposomal membrane, (d) intracellular
apoptotic body.The hypothesis
Considering the various obstacles in employing the che-
motherapeutic agents and the problems in their delivery,
we suggest ACPN as a chemotherapeutic agent in order
to be served in cancer treatment. In order to employ
ACPN for this purpose, it should be loaded in a liposo-
mal shell decorated with TLs and CPPs. As it can be
seen in Figure 1a, a designed platform comprises the
ACPNs, which are trapped in a liposomal shell, and fol-
ate as TL and TAT as CPP which are both positioned on
the surface of the liposome.
All the studies which have been done up to now, in
order to study the toxicity of CPN, are focused on
HANs. The other phases of calcium phosphate minerals
have not been investigated concerning their nanotoxi-
city. It should be noticed that the particle could not be
toxic by itself. However, the products of particle dissol-
ution and their effect on cellular mechanism lead to the
induced cytotoxicity. Considering the HANs dissolution,
Ca2+, PO4
3−, and OH− are the ions (products) which
leach out into the biological medium surrounding the
particle. Hence, we hypothesize that ACPN could be
more capable of inducing the apoptosis in comparison
to HAN. In fact, the amorphous phase of calcium phos-
phate is far more degradable than the crystalline phases
of calcium phosphate minerals such as hydroxyapatite. It
is worthy of mention that the apoptosis could be trig-
gered while [Ca2+]c augments. This fact suggests that theism of action. (a) the structure of the platform, (b) targeting on
release of ACPNs, (e) explosion of cancer cell into a cascade of
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it necessitates delivering the cargo to cytosol through an
endosomal escape pathway and the best condition hap-
pens when the endocytosis does not occur. Therefore,
the ACPN should be trapped in a liposomal capsule in
order to deliver the nanoparticles through endosomal es-
cape pathway. Although employment of liposome could
lead to endosomal escape, it is demonstrated that pres-
ence of TAT peptides on the surface of the platform sig-
nificantly enhances the efficacy of intracellular delivery.
Effective elimination of foreign materials from the
circulation by the reticuloendothelial system (RES) is
counted as one of the major problems of drug delivery
system [29]. While nanoparticles have solved many
problems in drug delivery, elimination by the RES has
remained an obstacle up to now. Nanoparticle size and
surface charge are the two major properties strongly in-
fluencing the elimination by this system [30,31]. Al-
though the main established mechanisms for clearance
of calcium phosphates are phagocytosis and acidification
[32], the RES is also capable of eliminating them [33].
Since CPNs are advantageous for the delivery of thera-
peutics [34], for improving the efficiency of therapy,
evading RES seems necessary for nanoparticles. In this
regard, the prepared platform should also be superficially
decorated with folate in order to enhance the cell-
specific delivery of the ACPN.
Testing the hypothesis
Contrary to the previous studies, we believe that ACPN
could be more efficient in inducing apoptosis in cells,
when they are delivered into the cytosol. This hypothesis
is based on this fact that the elevation in [Ca2+]c could
lead to apoptosis induction through both caspase-
dependent and caspase-independent pathways [35,36].
According to far higher dissolution rate of ACPN in
comparison to HAN [37], more calcium concentration
can be provided through the dissolution of ACPN in the
cytosol. According to the mentioned studies, the HAN
was just mediated with the cells. Accordingly, it is re-
ported that nanoparticles escaping from endosomes are
located in the cytosol and their dissolution resulted in
the elevation of [Ca2+]c [17], while no endosomal escape
platform was provided. In the case of employing ACPN,
higher elevation of [Ca2+]c is rapidly provided and the
cell lacks the appropriate amount of time to pump out
the extra intracellular calcium [38]. Hence, the delivery
platform is designed in a way that delivers the ACPN
into the cytosol utilizing a liposomal capsule [39]. The
presence of this capsule results in the endosomal escape
of the trapped ACPNs and the nanoparticles could be
released into the cytosol; although, like other experi-
ments, efficacy matters. In order to enhance the efficacy
of endosomal escape, the surface of the liposome shouldbe decorated with TAT peptides which dramatically raise
the rate of intracellular delivery [40]. TAT peptide mole-
cules should be attached on the liposome surface via
pNP-PEG-PE spacer [41]. Folate is often used as a tar-
geting ligand which has high specificity and affinity for
cell surface to the folate receptor, which is over-
expressed in some cancer cells including the breast,
lung, kidney, ovary, and brain, among others [42]. Folate
could be attached on the liposome surface utilizing
DSPE-PEG-FOL [43]. The presence of polyethylene gly-
col (PEG) could provide a protective shield which leads
to the avoidance of immune detection [44].
The hypothesized delivery platform has the potential
to target cancer cells through binding the targeting
ligands to Folate receptors. While the cell finds the
specific cells, TAT peptide can generate saddle-splay
membrane curvature and enter through an induced pore
[45]; thereafter, liposome fusion happens, and conse-
quently, the ACPNs enter the cytosol. As is mentioned
before, dissolution of each ACPN results in [Ca2+]c ele-
vation which eventually leads to cell death through the
triggering of apoptosis Figure 1b,c,d,e.
In order to find the appropriate dosage of ACPN for
apoptosis induction, an in vitro experiment should be
conducted. A type of cancer cell such as glioma cell is
cultured. Since in this part of study, targeting is out of
importance, the platforms are prepared in the absence of
folate. ACPN-loaded platforms, without a targeting lig-
and, are added to the culture dish. Regarding the fact
that elevation in [Ca2+]c determines when the cell starts
apoptosis, in this part of study, the point is to find the
amount of [Ca2+]c introduced by each ACPN. Hence,
measurement of [Ca2+]c could be performed by monitor-
ing Fura-2 fluorescence of cancer cells adhered to the
dish using a proper imaging system. Fura-2 is loaded
into the cells by the proper amount of incubation time.
In order to investigate the integrity of cell membrane,
which is related to [Ca2+]c, Fura-2/propidium iodide
assay is employed. Further details for both measure-
ments are presented by Ewence et al. [20] (Figure 2a).
Obtained data from this part of study shows appropriate
dosage of ACPNs and efficient exposure time. These re-
sults are based on the type of cancer cell that has been
experimented.
Due to the fact that this platform is decorated with fol-
ate as a targeting ligand, in order to investigate the effi-
ciency of the method and tumor accumulation of ACPN,
an in vitro experiment should be conducted. In this re-
gard, the proper dosage of ACPN should be injected
intravenously into a mouse bearing glioma xenograft,
according to a predetermined schedule. Since the injec-
tion is intravenous and not intratumoral, the platform
should be decorated by folate. The size of tumors is
measured in different intervals. Moreover, the tissue of
Figure 2 Experimentation with the developed platform: (a) in vitro study, (b) in vivo study.
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transferase dUTP nick end labeling (TUNEL) assay in
order to compare the amount of apoptotic cells (Figure 2b).
Implications of the hypothesis
Utilization of chemotherapeutic agents has been com-
mon for cancer treatment up to now. For efficient em-
ployment of such chemotherapeutic agents, appropriate
carriers should be employed. Many attempts have been
made to overcome the obstacles that hinder drug deliv-
ery system by applying nanotechnology to the prepar-
ation of suitable carriers. Even though nanotoxicity has
adverse effect on normal cells, such toxicity could be
employed to kill abnormal cells. As it is well proven,
both chemotrapeutics and nanoparticles have induced
toxicity to normal cells. Reducing this risk is the biggest
challenge for both systems. ACPNs exactly meet these
conditions due to the fact that extracellularly released
nanoparticles cleared through the RES, although the par-
ticles should be targeted by the suggested platform. Re-
garding the suggested platform, the RES could not
hinder circulation. The employment of PEG on the sur-
face of the liposome could result in a structure that pro-
longs circulation of the trapped drug, or in this study,
ACPNs. Moreover, macrophages in the RES located in
the liver and the spleen take up particles bound with
serum proteins; therefore, surface modification by PEG
reduces the opsonization of liposomes and reduces the
clearance by the RES, leading to enhanced pharmacoki-
netic properties [46]. Evading the RES will result in the
effective accumulation of ACPNs in the tumor by theenhanced permeability and retention (EPR) effect. This
effect facilitates drug release within the target tissues. In
this study, employment of folate as a targeting ligand
also results in EPR elevation [47]. In the near future,
probably lots of these platforms will be developed in
order to avoid drug delivery obstacles, although this hy-
pothesis is the first one of its kind.
Although bioaccumulation of ACPNs has not been
studied in particular, the distribution of HANs in mouse
organs was studied via intravenous administration. Ac-
cordingly, after 1 h of HANs circulation, the lung, liver,
and spleen contained most concentration of the nanopar-
ticles, which were sixfold higher than other organs. After
72 h, however, the amount of these nanoparticles de-
creased significantly in three organs, suggesting that the
HANs can be metabolized or excreted through these or-
gans. A gradual reduction in the concentration of
HANs was also detected in other organs which sug-
gests that considerable amount of nanoparticles have
been metabolized or excreted. It is worthy of mention
that this amount remained constant in the bone. Inter-
estingly, it was reported that the concentration of cal-
cium always increases with time in the excrement of
mice. It can be obviously attributed to the macro-
phages in the spleen, lung, and liver, where HANs are
captured in. The nanoparticles in macrophages can be
metabolized by the common bile duct and finally ex-
cluded from the body via feces. Moreover, it was found
that only very low concentration of calcium is detected
in the urine, suggesting nanoparticles are not excreted
from the body via the kidney [48].
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in cancer cells, although further consideration is needed in
order to find the critical dosage of ACPN which should be
uptaken by specific cancer cells to provide the appropriate
[Ca2+]c elevation for triggering apoptosis and avoiding ne-
crosis [49]. Selection of an appropriate ligand with suitable
water solubility should also be investigated in order to en-
hance the cell-specific targeting [50]. There are also some
issues on calcium-phosphate ratio in ACPN which affect
the rate of dissolution in biological mediums [37]. Under-
standing this ratio could also influence the rate of apoptosis
induction, so it needs to be considered. Regarding the
induction of apoptosis by nanoparticles such as ACPNs,
we propose ‘Nanoptosis’ as a scientific name for this
phenomenon. Consequently, the nanoparticles that could
result in Nanoptosis are called ‘Nanoptogenics’.
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